Rho GTPase activating protein 17 (ARHGAP17)

Rho GTPase activating protein 17 (ARHGAP17) is an enzyme that acts as a GTPase-activating protein (GAP) for members of the Rho family small G proteins, primarily targeting CDC42, RAC1, and RHOA, converting them from active GTP-bound forms to inactive GDP-bound states[1][5][8]. ARHGAP17 functions as a crucial regulator of intracellular signaling, modulating actin cytoskeleton dynamics, cell polarity, tight junction integrity, and vesicle trafficking[1][5][6][7]. Its regulatory activity is essential for maintaining epithelial and mucosal barrier function (particularly in the intestine), and its deficiency leads to increased intestinal permeability and heightened susceptibility to inflammatory injury[6]. In platelets, ARHGAP17 modulates Rac1 and suppresses cell migration[1]. In epithelial and cancer cells, ARHGAP17 acts as a tumor suppressor by limiting proliferative and oncogenic signaling pathways such as PI3K/AKT and Wnt/β-catenin; its downregulation enhances proliferation and contributes to malignancy, while overexpression has anti-tumor effects and promotes chemosensitivity[1][4][5]. Tissue-specific isoforms, such as the brain-specific BARGIN, are implicated in localized Rac1 inactivation and neurodevelopmental processes, with possible implications in neurodegenerative conditions[1]. Overall, ARHGAP17 is a multifunctional regulatory protein that influences key aspects of cellular organization, signaling, and disease pathogenesis through its modulation of Rho family GTPase activity[1][5][6][8].

Other names

RICH1NADRINWBP15FLJ10308FLJ13219MSTP066MSTP110RICH-1PP367PP4534RhoGAP interacting with CIP4 homologs protein 1neuron-associated developmentally regulated proteinBARGIN